Bright Minds Biosciences’ (DRUG) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Bright Minds Biosciences (NASDAQ:DRUG) in a research report sent to investors on Friday morning,Benzinga reports. Chardan Capital currently has a $80.00 price objective on the stock.

Several other research firms have also commented on DRUG. Cantor Fitzgerald reissued an “overweight” rating on shares of Bright Minds Biosciences in a research note on Monday, December 1st. BTIG Research began coverage on Bright Minds Biosciences in a report on Monday, September 8th. They issued a “buy” rating and a $72.00 price target on the stock. Zacks Research downgraded Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 2nd. HC Wainwright restated a “buy” rating and issued a $115.00 target price on shares of Bright Minds Biosciences in a report on Tuesday. Finally, Wall Street Zen raised Bright Minds Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $90.00.

Bright Minds Biosciences Trading Up 6.9%

Shares of Bright Minds Biosciences stock opened at $83.46 on Friday. Bright Minds Biosciences has a 52 week low of $23.17 and a 52 week high of $97.75. The stock has a market cap of $650.15 million, a PE ratio of -68.41 and a beta of -6.15. The company’s 50-day moving average price is $69.83 and its two-hundred day moving average price is $51.46.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DRUG. Police & Firemen s Retirement System of New Jersey purchased a new stake in Bright Minds Biosciences in the 2nd quarter worth about $28,000. JPMorgan Chase & Co. increased its holdings in shares of Bright Minds Biosciences by 624.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after purchasing an additional 1,873 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Bright Minds Biosciences in the third quarter worth approximately $58,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Bright Minds Biosciences during the second quarter worth approximately $66,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bright Minds Biosciences during the third quarter worth approximately $73,000. 40.52% of the stock is owned by institutional investors and hedge funds.

More Bright Minds Biosciences News

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $115 price target and highlighted long‑term upside (they also raised a FY2030 EPS view). That bullish anchor likely supports investor demand. HC Wainwright Reiterates Buy
• Positive Sentiment: Several trading reports note intraday gains and elevated activity (recent intraday prints showed multi‑percent increases), suggesting fresh buying interest and momentum among traders. Intraday Trading Report
• Neutral Sentiment: Technical/contextual datapoints (50‑day and 200‑day moving averages, 52‑week range, and recent volume spike relative to the 83k avg) are attracting attention but are descriptive rather than directional on their own. MarketBeat DRUG Summary
• Negative Sentiment: Chardan Capital reaffirmed a “Buy” but set an $80 price target — below the current price — which could limit near‑term upside or prompt profit‑taking by traders who watch PT arbitrage. Chardan Reaffirms Buy TickerReport
• Negative Sentiment: HC Wainwright cut multiple near‑term EPS forecasts (Q1–Q4 2026, FY2026–FY2029), signaling larger short‑term losses than previously expected — a potential negative for sentiment until clinical or financial catalysts reappear. HC Wainwright Estimates Update

About Bright Minds Biosciences

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.